Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Health Canada approves AbbVie's eight-week MAVIRET regimen for acute and chronic hepatitis C
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
Nimbus Therapeutics partners with Lilly to develop oral obesity treatment
BioArctic and Eisai secure Chinese acceptance for subcutaneous Leqembi filing
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Nanjing Delova Biotech reports positive Phase 3 trial results for QP-6211 for postoperative pain
MetaVia reports positive results from Phase 1 clinical trial in obesity